M1559
Moxonidine hydrochloride
≥98%
别名:
4-Chloro-6-methoxy-2-methyl-5-(2-imidazolin-2-yl)aminopyrimidine hydrochloride, BDF-5895
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C9H12ClN5O · HCl
化学文摘社编号:
分子量:
278.14
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98%
Quality level:
产品名称
Moxonidine hydrochloride, ≥98%
InChI
1S/C9H12ClN5O.ClH/c1-5-13-7(10)6(8(14-5)16-2)15-9-11-3-4-12-9;/h3-4H2,1-2H3,(H2,11,12,15);1H
SMILES string
Cl.COc1nc(C)nc(Cl)c1NC2=NCCN2
InChI key
ZZPAWQYZQVUVHX-UHFFFAOYSA-N
assay
≥98%
originator
Solvay
Quality Level
Gene Information
human ... ADRA2A(150), ADRA2B(151), ADRA2C(152), NISCH(11188)
Application
Moxonidine hydrochloride has been used:
- as a standard to study its blood-brain barrier (BBB) permeability in porcine brain lipid extract by parallel artificial membrane permeability assay (PAMPA) method
- as a standard to study the chromatographic behavior and lipophilicity by reversed-phase thin-layer chromatography (RP-TLC)
- as an imidazoline I1 receptor agonist to study its effects on excitatory inputs in airway vagal preganglionic neuron (AVPN)
Biochem/physiol Actions
Moxonidine is a selective high-affinity imidazoline I1-receptor agonist and a selectively low-affinity α2-adrenoceptor agonist. It exhibits anti-hypertensive properties by reducing blood pressure efficiently. Moxonidine also exhibits spinal analgesic activity through the α2C-adrenoceptor component.
Features and Benefits
This compound is featured on the Imidazoline Binding Sites page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Solvay. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
Jelica Vucicevic et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 68, 94-105 (2014-12-30)
Imidazoline receptor ligands are a numerous family of biologically active compounds known to produce central hypotensive effect by interaction with both α2-adrenoreceptors (α2-AR) and imidazoline receptors (IRs). Recent hypotheses connect those ligands with several neurological disorders. Therefore some IRs ligands
C Bing et al.
British journal of pharmacology, 127(1), 35-42 (1999-06-16)
The antihypertensive agent moxonidine, an imidazoline Ii-receptor agonist, also induces hypophagia and lowers body weight in the obese spontaneously hypertensive rat, but the central mediation of this action and the neuronal pathways that moxonidine may interact with are not known.
J Greven et al.
Naunyn-Schmiedeberg's archives of pharmacology, 364(6), 496-500 (2002-01-05)
Moxonidine is a centrally acting antihypertensive agent which has been found to exert its blood pressure lowering effect by interaction with (alpha2-adrenoceptors and imidazoline receptors of the I(1)-type. These receptors have also been demonstrated to be present in the rat
Xujiao Zhou et al.
Brain research, 1732, 146695-146695 (2020-02-03)
As an imidazoline I1 receptor agonist with very weak binding affinity for α2-adrenoceptors, moxonidine is commonly used in the treatment of hypertension. Moxonidine also has been implicated to act centrally to reduce airway vagal outflow. However, it is unknown at
Estimation of lipophilicity and retention behavior of some alpha adrenergic and imidazoline receptor ligands using RP-TLC
Mohamed S, et al.
Journal of Liquid Chromatography and Related Technologies, 37(20), 2829-2845 (2014)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持